Biocon Pharma, Carnegie Pharma gain USFDA tentative nod for Rifaximin Tablets to treat irritable bowel syndrome with diarrhea

Written By :  Ruchika Sharma
Medically Reviewed By :  Dr. Kamal Kant Kohli
Published On 2025-10-07 05:27 GMT   |   Update On 2025-10-07 05:27 GMT
Advertisement

Bangalore: Biocon has announced that Biocon Pharma Limited, a wholly owned subsidiary of the Company, in partnership with Carnegie Pharmaceuticals LLC, has received tentative approval from the U.S. Food and Drug Administration (U.S. FDA) for the Abbreviated New Drug Application (ANDA) for Rifaximin Tablets, 550 mg.

Rifaximin tablets are a rifamycin antibacterial indicated for reducing the risk of overt hepatic encephalopathy (HE) recurrence and to treat irritable bowel syndrome with diarrhea (IBS-D) in adults.

Advertisement

Irritable Bowel Syndrome is a common gastrointestinal disorder that affects the large intestine, leading to symptoms like abdominal pain, bloating, and changes in bowel habits. 

Read also: Biocon Biologics, Amgen strike settlement, clear path for Bosaya, Aukelso in US

Biocon Limited, publicly listed in 2004, is a global biopharmaceutical company. It has developed and commercialized novel biologics, biosimilars and complex small molecule APIs in India and several key global markets, as well as generic formulations in the US and Europe.

Read also: Biocon Pharma bags tentative USFDA nod for diabetes medicine Sitagliptin



Tags:    

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News